Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 7;31(3):334-340.e5.
doi: 10.1016/j.stem.2024.02.001. Epub 2024 Feb 8.

Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate

Xiaomeng Hu  1 , Kathy White  1 , Chi Young  1 , Ari G Olroyd  1 , Paul Kievit  1 , Andrew J Connolly  1 , Tobias Deuse  1 , Sonja Schrepfer  2
Affiliations
Free article

Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate

Xiaomeng Hu et al. Cell Stem Cell. .
Free article

Abstract

Allogeneic transplantation of pancreatic islets for patients with difficult-to-control diabetes mellitus is severely hampered by the requirement for continuous immunosuppression and its associated morbidity. We report that allogeneic transplantation of genetically engineered (B2M-/-, CIITA-/-, CD47+), primary, hypoimmune, pseudo-islets (p-islets) results in their engraftment into a fully immunocompetent, diabetic non-human primate wherein they provide stable endocrine function and enable insulin independence without inducing any detectable immune response in the absence of immunosuppression. Hypoimmune primary p-islets may provide a curative cell therapy for type 1 diabetes mellitus.

Keywords: hypoimmune; immune evasive.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests All experiments were conducted by or on behalf of Sana Biotechnology, Inc. and no data from UCSF or OHSU were used. A.J.C. and T.D. performed the work in this manuscript as consultants to Sana Biotechnology, Inc. T.D. owns stock in Sana Biotechnology, Inc. P.K. has no financial disclosures. All other authors are employees of and own stock in Sana Biotechnology, Inc. X.H. and S.S. are inventors on a patent (International Application No: PCT/US2022/074878; Title “Genetically modified primary cells for allogeneic cell therapy”).

LinkOut - more resources